Chiara Zecca1,2, G Bellavia3, L Brambilla3, L P Gutierrez3, C Gerardi4, A M Fiori3, L R Bernardini3, G Camera3, G Disanto5, L Petrini5, J Perugini3, C G Antozzi3, V Torri Clerici3, A Bellino3, P A Confalonieri3, C Gobbi5, R E Mantegazza3, S Rossi3. 1. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland. chiara.zecca@eoc.ch. 2. Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy. chiara.zecca@eoc.ch. 3. Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy. 4. IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. 5. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland.
Abstract
BACKGROUND: Glatiramer acetate (GA) 20 mg/day (GA20) is associated with immediate post-injection reactions (PIRs). For convenience of use, approved GA 40 mg three times weekly (GA40) delivers a similar weekly dose. The dose and concentration of a single GA40 injection are, however, twice as high as for GA20, and post-injection adverse events may differ. Cases of atypical PIRs to GA40 prompted us to systematically monitor such events. OBJECTIVE: The aim was to characterize atypical PIRs in multiple sclerosis (MS) patients treated with GA40. METHODS: Clinical practice data were prospectively collected in consecutive relapsing-remitting MS patients. Descriptive statistics for categorical and continuous variables, Mann-Whitney and Chi-squared tests for baseline comparisons, and Cox regression models for association of variables to first atypical PIRs were applied. RESULTS: Forty-six out of 173 patients (26.6%) given GA40 experienced any PIRs. Of those, 38 (22.0%) had atypical, 14 (8.1%) had combined typical and atypical, and 26 (15.0%) had recurrent atypical PIRs, most frequently shivering (13.3%) and nausea/vomiting (8.1%). Compared to typical PIRs, onset of atypical PIRs was significantly delayed (median 30 vs 1 min, p < 0.0001), and their median duration longer (median 120 vs 6 min, p = 0.00013). Previous exposure to GA20 was associated with a lower risk of atypical PIRs [hazard ratio (HR) = 0.35, 95% confidence interval (CI) 0.17-0.72, p = 0.0039]. Patients experiencing PIRs with GA20 were at elevated risk for atypical PIRs with GA40 (HR = 5.75, 95% CI 1.66-19.94, p = 0.0059). CONCLUSIONS: Atypical PIRs with GA40, especially gastrointestinal symptoms and/or fever/shivering, had a delayed onset and occurred in a significant proportion of our patients. Their real prevalence should be assessed in appropriately designed studies accounting for nocebo responses. Initial dose titration might reduce PIR frequency.
BACKGROUND:Glatiramer acetate (GA) 20 mg/day (GA20) is associated with immediate post-injection reactions (PIRs). For convenience of use, approved GA 40 mg three times weekly (GA40) delivers a similar weekly dose. The dose and concentration of a single GA40 injection are, however, twice as high as for GA20, and post-injection adverse events may differ. Cases of atypical PIRs to GA40 prompted us to systematically monitor such events. OBJECTIVE: The aim was to characterize atypical PIRs in multiple sclerosis (MS) patients treated with GA40. METHODS: Clinical practice data were prospectively collected in consecutive relapsing-remitting MSpatients. Descriptive statistics for categorical and continuous variables, Mann-Whitney and Chi-squared tests for baseline comparisons, and Cox regression models for association of variables to first atypical PIRs were applied. RESULTS: Forty-six out of 173 patients (26.6%) given GA40 experienced any PIRs. Of those, 38 (22.0%) had atypical, 14 (8.1%) had combined typical and atypical, and 26 (15.0%) had recurrent atypical PIRs, most frequently shivering (13.3%) and nausea/vomiting (8.1%). Compared to typical PIRs, onset of atypical PIRs was significantly delayed (median 30 vs 1 min, p < 0.0001), and their median duration longer (median 120 vs 6 min, p = 0.00013). Previous exposure to GA20 was associated with a lower risk of atypical PIRs [hazard ratio (HR) = 0.35, 95% confidence interval (CI) 0.17-0.72, p = 0.0039]. Patients experiencing PIRs with GA20 were at elevated risk for atypical PIRs with GA40 (HR = 5.75, 95% CI 1.66-19.94, p = 0.0059). CONCLUSIONS: Atypical PIRs with GA40, especially gastrointestinal symptoms and/or fever/shivering, had a delayed onset and occurred in a significant proportion of our patients. Their real prevalence should be assessed in appropriately designed studies accounting for nocebo responses. Initial dose titration might reduce PIR frequency.
Authors: Jerry S Wolinsky; T Erik Borresen; Dennis W Dietrich; Daniel Wynn; Yulia Sidi; Joshua R Steinerman; Volker Knappertz; Scott Kolodny Journal: Mult Scler Relat Disord Date: 2015-06-14 Impact factor: 4.339
Authors: M B Bornstein; A Miller; S Slagle; M Weitzman; H Crystal; E Drexler; M Keilson; A Merriam; S Wassertheil-Smoller; V Spada Journal: N Engl J Med Date: 1987-08-13 Impact factor: 91.245
Authors: Omar Khan; Peter Rieckmann; Alexey Boyko; Krzysztof Selmaj; Natalia Ashtamker; Mat D Davis; Scott Kolodny; Robert Zivadinov Journal: Mult Scler Date: 2016-08-08 Impact factor: 6.312
Authors: G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi Journal: Lancet Date: 2009-10-06 Impact factor: 79.321